Literature DB >> 12776267

Are children with idiopathic nephrotic syndrome at risk for metabolic bone disease?

Sanjeev Gulati1, Madan Godbole, Uttam Singh, Kiran Gulati, Arvind Srivastava.   

Abstract

BACKGROUND: Children with idiopathic nephrotic syndrome (INS) may be at risk for metabolic bone disease (MBD) because of biochemical derangements caused by the renal disease, as well as steroid therapy. No large study to date has shown conclusively that these children are prone to MBD.
METHODS: We prospectively studied 100 consecutive children with INS for clinical, biochemical, and radiological evidence of MBD. These children were treated with prednisone as follows: initial episode, prednisone, 60 mg/m2/d for 6 weeks, followed by 40 mg/m2 on alternate days for 6 weeks. Relapses were treated with 60 mg/m2/d until remission for 3 days, followed by 40 mg on alternate days for 4 weeks and tapered by 10 mg/m2/wk. Osteoporosis is defined as a bone mineral density (BMD) value evaluated by dual-energy X-linked absorptiometry of the lumbar spine of a z score of 2.5 SDs less than the mean. Univariate and multivariate analyses were performed to analyze for factors predictive of low BMD z score. Children were divided into two groups: those who had received repeated courses of steroid therapy (group II: frequent relapsers (FRs), steroid dependent (SD), or steroid nonresponders (SNRs) versus those who had received infrequent courses (group I: infrequent relapsers).
RESULTS: Twenty-two of 100 children (22%) had osteoporosis. Comparing clinical features, we observed that 6 of 70 children in group II were symptomatic (hypocalcemic signs) compared with none of 30 children in group I (P = 0.10). However, children in group II had significantly lower mean BMD z scores compared with group I (-1.65 +/- 1.35 versus -1.08 +/- 1.0; P = 0.01). Also, 20 of 70 children in group II had osteoporosis compared with 2 of 30 children in group I (P = 0.012). Children in group II had been administered significantly greater doses of steroids compared with group I (P < 0.00001). On multivariate analysis, factors predictive of a low BMD score were older age at onset (P = 0.000), lower total calcium intake (P = 0.000), and greater cumulative steroid dose (P = 0.005).
CONCLUSION: Children with INS are at risk for low bone mass, especially those administered higher doses of steroids (FRs, SD, or SNRs). These children should undergo regular BMD evaluations, and appropriate therapeutic interventions should be planned.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12776267     DOI: 10.1016/s0272-6386(03)00348-2

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  19 in total

1.  Vertebral fractures despite normal spine bone mineral density in a boy with nephrotic syndrome.

Authors:  Anne Marie Sbrocchi; Frank Rauch; MaryAnn Matzinger; Janusz Feber; Leanne M Ward
Journal:  Pediatr Nephrol       Date:  2010-10-05       Impact factor: 3.714

2.  Bone disease in nephrotic syndrome--prevention is better than cure.

Authors:  Sanjeev Gulati; Kiran Gulati
Journal:  Pediatr Nephrol       Date:  2005-01       Impact factor: 3.714

3.  The characteristics of relapse in adult-onset minimal-change nephrotic syndrome.

Authors:  Takashi Takei; Minako Koike; Koichi Suzuki; Satsuki Shirota; Mitsuyo Itabashi; Shigeru Ohtsubo; Hidekazu Sugiura; Keiko Suzuki; Chiari Kojima; Masaki Takahashi; Jun Ino; Tetsuya Ogawa; Keiko Uchida; Ken Tsuchiya; Wako Yumura; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2007-09-28       Impact factor: 2.801

4.  Calcium and vitamin D for osteoprotection in children with new-onset nephrotic syndrome treated with steroids: a prospective, randomized, controlled, interventional study.

Authors:  Surabhi Choudhary; Indira Agarwal; Mandalam S Seshadri
Journal:  Pediatr Nephrol       Date:  2014-01-12       Impact factor: 3.714

Review 5.  Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window.

Authors:  Uwe Querfeld; Robert H Mak
Journal:  Pediatr Nephrol       Date:  2010-06-22       Impact factor: 3.714

6.  The effect of vitamin D and calcium supplementation in pediatric steroid-sensitive nephrotic syndrome.

Authors:  Sushmita Banerjee; Surupa Basu; Ananda Sen; Jayati Sengupta
Journal:  Pediatr Nephrol       Date:  2017-07-19       Impact factor: 3.714

7.  Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children.

Authors:  Anna Wasilewska; Agnieszka Rybi-Szuminska; Walentyna Zoch-Zwierz
Journal:  Pediatr Nephrol       Date:  2010-07-04       Impact factor: 3.714

8.  Bone mineral density in children with steroid-sensitive nephrotic syndrome.

Authors:  O P Mishra; S K Meena; S K Singh; R Prasad; R N Mishra
Journal:  Indian J Pediatr       Date:  2009-12       Impact factor: 1.967

9.  Vitamin D in nephrotic syndrome remission: a case-control study.

Authors:  Sushmita Banerjee; Surupa Basu; Jayati Sengupta
Journal:  Pediatr Nephrol       Date:  2013-05-25       Impact factor: 3.714

10.  Changes in the Dickkopf-1 and tartrate-resistant acid phosphatase 5b serum levels in preschool children with nephrotic syndrome.

Authors:  Jianjiang Zhang; Huiqin Zeng; Shuqin Fu; Peipei Shi; Miao Wang; L I Guo
Journal:  Biomed Rep       Date:  2016-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.